News >

Choueiri Discusses Avelumab/Axitinib, Other Novel RCC Combos

Angelica Welch
Published: Thursday, Aug 03, 2017

Toni K. Choueiri, MD

Toni K. Choueiri, MD
Results from a phase Ib trial presented at the 2017 ASCO Annual Meeting showed strong activity with the combination of the PD-L1 inhibitor avelumab (Bavencio) and the VEGF inhibitor axitinib (Inlyta) in patients with advanced renal cell carcinoma (RCC).

during ASCO, the study’s lead author, Toni Choueiri, MD, senior physician and director of the Kidney Cancer Center at Dana-Farber Cancer Institute, reflected on the avelumab/axitinib results and other emerging combos in RCC.

OncLive: Can you give an overview of this study?

Choueiri: Drugs that target the VEGF or its receptor have been the cornerstone of treatment for 10 years now, and we were looking for a combination with another active drug for a long time. Then the PD-1/PD-L1 inhibitors came and generated this data, with phase I and up to phase III trials in this disease. Based on that, now you have 3 abstracts selected for oral presentation that deal with combining a VEGF inhibitor and a PD-1/PD-L1 inhibitor. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication